$49.43
Value $3.1B
GRDN and MDLZ stock compared: price, dividend, valuation and results, from SEC filings.
$49.43
Value $3.1B
$67.54
Value $86.6B
Guardian Pharmacy Services (GRDN) has a market value of $3.1B and Mondelez International (MDLZ) $86.6B. Over the last year, with dividends, GRDN moved +69.2% and MDLZ +23.1%. The P/E is 41.9 for GRDN and 21.2 for MDLZ. Dividend yield: GRDN none, MDLZ 2.99%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
GRDN$3.1B
MDLZ$86.6B
MDLZ is 28 times GRDN
Revenue, 12 months
GRDN$1.5B
MDLZ$39.9B
MDLZ is 27 times GRDN
Net income, 12 months
GRDN$75M
MDLZ$4.1B
MDLZ is 55 times GRDN
Operating margin
GRDN6.5%
MDLZ13.7%
7.2 points apart
ROIC
GRDN28.8%
MDLZ9.1%
19.7 points apart
P/E
GRDN41.9
MDLZ21.2
GRDN is 2.0 times MDLZ
Dividend yield
GRDN0.0%
MDLZ3.0%
3.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
GRDN+69.2%
MDLZ+23.1%
| Period | GRDNWith dividends | MDLZWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +69.2%Price +69.2% | +23.1%Price +18.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
GRDNGuardian Pharmacy ServicesMDLZMondelez International
| Price | $49.43 | $67.54 |
|---|---|---|
| Market value | $3.1B | $86.6B |
| Enterprise value (EV) | $3.0B | $105B |
| P/E | 41.9 | 21.2 |
| P/E, 5-year median | – | 21.8 |
| P/B | 11.2 | 3.3 |
| EV/EBIT | 32.0 | 19.2 |
| Free cash flow yield | 2.8% | 4.2% |
| Revenue, 12 months | $1.5B | $39.9B |
|---|---|---|
| Net income, 12 months | $75M | $4.1B |
| Free cash flow, 12 months | $87M | $3.7B |
| Earnings per share, 12 months | $1.18 | $3.18 |
| Revenue growth, year on year | 17.9% | 5.8% |
| Revenue growth a year, past | +17.9%over 1 years | +7.7%over 5 years |
| EPS growth a year, past | – | -5.2%over 5 years |
| Gross margin | 22.5% | 34.3% |
|---|---|---|
| Operating margin | 6.5% | 13.7% |
| Net margin | 5.1% | 10.2% |
| ROIC | 28.8% | 9.1% |
| ROE | 31.6% | 15.6% |
| Cash | $120M | $1.7B |
|---|---|---|
| Total debt | $36M | $20.6B |
| Net debt / EBITDA | -1.0 | 2.7 |
| Interest cover | 145.3× | 9.2× |
| Dividend yield | – | 3.0% |
|---|---|---|
| Dividend per share, 12 months | – | $2.02 |
| Dividend growth a year, past | – | +10.4%over 5 years |
| Buyback yield | – | 2.8% |
| Shareholder yield | – | 5.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Mondelez International ($86.6B) is about 27.6 times Guardian Pharmacy Services ($3.1B), at today's prices.
Since November 14, 2025, GRDN's price moved +69.2% and MDLZ's +18.8%. With dividends: GRDN +69.2% (+69.2% a year), MDLZ +23.1% (+23.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Guardian Pharmacy Services and 2.99% for Mondelez International. Over the last twelve months they paid – and $2.02 per share.
At today's price, the P/E is 41.9 for GRDN and 21.2 for MDLZ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 5.1% for Guardian Pharmacy Services and 10.2% for Mondelez International, and the operating margin 6.5% and 13.7%. Revenue was $1.5B and $39.9B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.